Business
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a
About this update from Ataibeckley Inc.
[{"type":"text","content":"NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: “Following the strategic combination of atai Life Sciences and Beckley Psytech completed last year and the recent corporate redomiciliation to the United States, we enter 2026 with meaningful momentum and a clear vision for the impact AtaiBeckley can deliver for people living with difficult-to-treat mental health conditions. Our pipeline is maturing at a pivotal moment for innovation in the mental health treatment landscape, and with financial resources expected to support operations into 2029, we are well prepared to execute. Our presence at the J.P. Morgan Healthcare Conference provides us with an important opportunity to engage with investors and strategic partners and highlight the progress we’ve made so far and the value we believe AtaiBeckley is positioned to deliver in the months and years ahead.” Recent Clinical Updates and Anticipated 2026 Milestones BPL-003: mebufotenin benzoate nasal spray for treatment-resistant depression (TRD) and alcohol use disorder Reported positive topline data from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 in patients with treatment-resistant depression (TRD) in July 2025. The study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose. Both 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8.Reported positive topline data from the eight-week open-label extension (OLE) study of the Phase 2b clinical trial of BPL-003 in patients with TRD in November 2025. The findings showed that a 12 mg dose of BPL-003, administered eight weeks...